Literature DB >> 20686912

Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Eleonore Fröhlich1.   

Abstract

Cutaneous malignant melanoma is the most aggressive skin cancer. It is also the most rapidly spreading cancer in terms of worldwide incidence. Although it is detected by simple inspection and can be relatively easily removed or treated, differential diagnosis to other melanocytic lesions, lack of prognostic markers, and no efficient treatment of advanced melanoma pose problems. Detection and targeting of proteases may represent a useful tool since they play a role in tumor cell metabolism, invasion, angiogenesis and metastasis. This review gives an overview of the role of proteases in development and progression of cutaneous malignant melanoma. In addition, regulation, activation, and interaction of proteases and their inhibitors are explained for tumors in general. The potential use of proteases as differential markers for melanoma mimicking melanocytic lesions, as biomarkers in tissues, and as prognostic serum markers is discussed. Current and future possibilities to target tumor proteases in therapy are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686912     DOI: 10.1007/s00018-010-0469-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  144 in total

1.  The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis.

Authors:  T Goldmann; L Suter; D Ribbert; F Otto
Journal:  Pathol Res Pract       Date:  1999       Impact factor: 3.250

2.  Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene.

Authors:  C G Huh; K Håkansson; C M Nathanson; U P Thorgeirsson; N Jonsson; A Grubb; M Abrahamson; S Karlsson
Journal:  Mol Pathol       Date:  1999-12

3.  Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.

Authors:  T D Brooks; J Slomp; P H Quax; A C De Bart; M T Spencer; J H Verheijen; P A Charlton
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma.

Authors:  B Stabuc; Z Mrevlje; J Markovic; M Stabuc-Silih
Journal:  Neoplasma       Date:  2006       Impact factor: 2.575

5.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.

Authors:  J Kanitakis; D Narvaez; A Claudy
Journal:  Melanoma Res       Date:  2002-06       Impact factor: 3.599

Review 7.  Melanoma, nevogenesis, and stem cell biology.

Authors:  James M Grichnik
Journal:  J Invest Dermatol       Date:  2008-10       Impact factor: 8.551

Review 8.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Authors:  M Schmitt; F Jänicke; N Moniwa; N Chucholowski; L Pache; H Graeff
Journal:  Biol Chem Hoppe Seyler       Date:  1992-07

9.  Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression.

Authors:  Heather Ervin; James L Cox
Journal:  Cancer Cell Int       Date:  2005-05-17       Impact factor: 5.722

10.  Cathepsin L increases invasion and migration of B16 melanoma.

Authors:  Zhen Yang; James L Cox
Journal:  Cancer Cell Int       Date:  2007-05-08       Impact factor: 5.722

View more
  9 in total

Review 1.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

2.  TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death.

Authors:  J-Y Chang; M-F Chiang; S-R Lin; M-H Lee; H He; P-Y Chou; S-J Chen; Y-A Chen; L-Y Yang; F-J Lai; C-C Hsieh; T-H Hsieh; H-M Sheu; C-I Sze; N-S Chang
Journal:  Cell Death Dis       Date:  2012-04-26       Impact factor: 8.469

3.  Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma - a preliminary study.

Authors:  Tatyana Vlaykova; Mateusz Kurzawski; Tanya Tacheva; Dimo Dimov; Maya Gulubova; Yovcho Yovchev; Stoyan Chakarov; Marek Drozdzik
Journal:  Biotechnol Biotechnol Equip       Date:  2014-11-13       Impact factor: 1.632

4.  Matrix metalloproteinase-3 gene promoter polymorphisms: A potential risk factor for pelvic organ prolapse.

Authors:  Charalampos Karachalios; Panagiotis Bakas; Georgios Kaparos; Styliani Demeridou; Ilias Liapis; Charalampos Grigoriadis; Aggelos Liapis
Journal:  Biomed Rep       Date:  2016-08-03

5.  Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.

Authors:  Joshua Jiawei Zhou; Yuanshen Huang; Xue Zhang; Yabin Cheng; Liren Tang; Xiaodong Ma
Journal:  Oncotarget       Date:  2017-09-27

6.  Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Authors:  Tiphaine Delaunay; Lydia Deschamps; Meriem Haddada; Francine Walker; Antoninus Soosaipillai; Feryel Soualmia; Chahrazade El Amri; Eleftherios P Diamandis; Maria Brattsand; Viktor Magdolen; Dalila Darmoul
Journal:  Mol Oncol       Date:  2017-08-11       Impact factor: 6.603

7.  Wogonin suppresses melanoma cell B16-F10 invasion and migration by inhibiting Ras-medicated pathways.

Authors:  Kai Zhao; Libin Wei; Hui Hui; Qinsheng Dai; Qi-Dong You; Qing-Long Guo; Na Lu
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

8.  Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse.

Authors:  Roxana Khazen; Sabina Müller; Nicolas Gaudenzio; Eric Espinosa; Marie-Pierre Puissegur; Salvatore Valitutti
Journal:  Nat Commun       Date:  2016-03-04       Impact factor: 14.919

9.  Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma.

Authors:  Idoia Ortega-Martínez; Jesús Gardeazabal; Asier Erramuzpe; Ana Sanchez-Diez; Jesús Cortés; María D García-Vázquez; Gorka Pérez-Yarza; Rosa Izu; Jose Luís Díaz-Ramón; Ildefonso M de la Fuente; Aintzane Asumendi; María D Boyano
Journal:  Int J Cancer       Date:  2016-06-11       Impact factor: 7.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.